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Summary. The current status of iodine 131 -radiolabeled 
monoclonal antibody G250 (mAb G250) in renal-cell car­
cinoma (RCC) is described. This mAb recognizes a tu­
mor-associated antigen that is expressed on the cell sur­
face o f almost all RCC but is not expressed on normal tis­
sues, with the exception of gastric mucosa and larger bile 
ducts. On the basis of these favorable characteristics, this 
mAb seemed a prime candidate for clinical investigations. 
Preclinical animal studies and ex vivo perfusion experi­
ments in tumor-bearing kidneys showed excellent target­
ing of mAb G250 to RCC tumors. Supported by these in­
vestigations, a phase I study was initiated to define the 
imaging and biodistribution characteristics of I3,I-labeled 
mAb G250 in RCC patients. Specific localized of [l3lI]- 
mAb G250 to G250-antigen-positive primary and metasta­
tic RCC was observed. In several patients, [131I]-mAb 
G250 imaging revealed thus far unrecognized, i.e., occult, 
disease. Values obtained for [131I]-mAb G250 uptake, rel­
ative as well as absolute, were among the highest reported 
for tumor biopsies obtained 8 days after intravenous mAb 
administration. The specific localization and high accu­
mulation encouraged us to begin a phase I/II radiotherapy 
trial with [i31I]-mAb G250. The maximal tolerable dose 
was reached at 90 mCi/m2 [131I]-mAb G250. In the subse­
quent phase I/II radiotherapy study, we observed stable 
disease in a great number of patients as well as minor re­
sponses in a small number of patients. Multiple treatments 
seemed necessary to achieve better response rates. How­
ever, anti-mouse responses prevented multiple dosing with 
the murine mAb G250, Therefore, we developed a chimeric 
version of mAb G250 (cG250), in which constant regions 
of the mouse immunoglobulin have been exchanged for 
human immunoglobulin regions. A phase I clinical trial 
with cG250 is ongoing and very encouraging. The general 
imaging and targeting characteristics of cG250 seem com­
parable with those of murine mAb G250. In the near fu­
ture the (radio)therapeutic possibilities of this promising 
mAb will be investigated.
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Monoclonal antibodies in renal-cell carcinoma
Since the development of technologies to generate mono­
clonal antibodies (mAbs) [10], much effort has been fo­
cused on the isolation of mAbs reactive with tumor anti­
gens for diagnostic and therapeutic applications [7, 8, 11, 
12, 16]. For tumor immunologists, the old dream of har­
nessing the exquisite specificity of antibodies to bind to tu­
mor-specific antigens and, thereby, to kill tumor cells, 
seemed finally within reach. However, in spite of intense 
research, the isolation of clinically relevant mAbs has been 
disappointing, mainly because of a lack of true tumor 
specificity. Preferably such mAbs are reactive with tumor- 
specific antigens (TSA) expressed by all tumor cells of a 
certain tumor type. However, unequivocal evidence for 
unique TSA in human malignancies remains lacking. Most 
human malignancies have weak, if any, detectable immuno­
genic properties, indicating that most human cancers either 
are nonimmunogenic or mediate strong immunomodul­
atory effects. Current mAbs of interest recognize tumor- 
associated antigens (TAA), which are either differentiation 
antigens that are (transiently) expressed during organogen­
esis or aberrantly expressed antigens that are (transiently) 
expressed elsewhere in nonrelated normal tissue(s).
A significant number of mAbs reactive with cell-sur­
face antigens of renal-cell carcinoma (RCC) have been 
identified [1, 6 , 9, 15, 19, 20, 24, 30, 35]. Their specificity
has been established primarily by immunohistochemistry. 
Less is known about their targeting abilities and their ther­
apeutic efficacy. The anti-RCC mAbs can be divided into 
two groups: mAbs recognizing differentiation antigens [1, 
6 , 9, 15, 20, 24, 30, 35] and mAbs recognizing RCC-TAA 
aberrantly expressed in RCC, i.e., recognizing an RCC 
antigen absent from normal kidney [6 , 9, 15, 19, 30]. 
MAbs of the latter category in general show very re­
stricted cross-reactivity with normal tissues as judged by 
immunohistochemistry. It is likely that these mAbs iden­
tify different RCC-TAA, since they display different reac­
tivity with normal tissues. The number of RCC-TAA is re­
markably high in comparison to TAA identified in other 
tumor types, with the exception of melanoma. It is tempt­
ing to speculate that these RCC-TAA function as targets
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of the (abortive) antitumor response that is sometimes ob­
served in RCC patients. In view of the restricted cross-re- 
activity with normal tissues in combination with expres­
sion of a given RCC-TAA in most RCC, these mAbs are 
prime candidates for clinical investigations.
Monoclonal antibody G250
One of the m A bs recognizing an RCC-TAA, mAb G25Ó, 
was obtained after fusion of spleen cells from a mouse im­
munized with fresh RCC homogenates [19]. Initially, 
G250 antigen expression was examined in 55 RCC; 42/47 
primary RCC showed homogeneous G250 antigen expres­
sion (89%), 4 tumors showed heterogeneous G250 anti­
gen expression, and only 1 primary tumor was completely 
G250-antigen-negative. M ore importantly, of 8 metas- 
tases examined, 5 showed homogeneous G250 expression 
(62%), 2 showed heterogeneous G250 expression, and 1 
failed to express G250 antigen [19]. With increased num­
bers of RCC being tested, no difference with respect to the 
percentage of RCC expressing G250 antigen has been ob­
served; in 77/95 primary RCC investigated, more than 
50% of tumor cells were scored positive (81%), and in an 
additional 8 primary RCC, tumor cells were stained, albeit 
with lower frequency, i.e., approximately 90% of primary 
RCC express G250 antigen. For the metastatic lesions, 
G250-positive tumor cells were noticed in 18 of 22 tumors 
(82%) examined, with homogenous staining occurring in
9 of 17 metastatic RCC examined (53%). In general, clear­
cell RCC tend to show homogenous G250 antigen expres­
sion, whereas non-clear-cell RCC show heterogenous G250 
expression. This RCC-TAA is absent from normal kidney 
and other normal tissues examined, with the exception of 
gastric mucosal cells and cells of the larger bile ducts. 
This antigen therefore meets closely the criteria for mAbs 
that might have clinical use.
Preclinical investigations
The targeting ability of mAb G250 was investigated in an 
RCC xenograft model [26]. BALB/c nu/nu mice xeno- 
grafted with hum an RCC and/or human non-RCC tumors 
were injected with 125I-labeled mAb G250 IgG l, F (ab’)2> 
or Fab’ [26]. Specific m Ab G250 accumulation was ob­
served for all antibody forms. G250-negative tumors did 
not show any m Ab G250 uptake, nor did the G250-posi- 
tive tumors show increased uptake of nonrelevant im ­
munoglobulin. Tumor/blood ratios were high in compari­
son with those obtained in other targeting studies in mice. 
Chiou et al. [4] studied mAb A 6H, which is reactive with 
a normal kidney-differentiation antigen, and found com ­
parable, relatively high tumor/blood ratios. This finding 
may be related to a general increase in the permeability of 
the vascular bed in RCC xenografts [23].
Higher m Ab G250 uptake was generally found with 
intact immunoglobulin than with mAb G250 F(ab’)2 or 
Fab’ fragments, associated most probably with the longer 
retention of the complete IgG, leaving the antibody more 
time to diffuse to the tum or cells. The lowest uptake was
observed for Fab' fragments, related to their short biolog­
ical half-life and lower avidity.
In addition to mouse targeting studies, tumor-bearing 
human kidneys were perfused ex vivo with radiolabeled 
mAb G250 [25]. After flushing of the specimens with 
preservation fluid immediately after surgery, the kidneys 
were perfused with 99mTc-labeled mAb G250. [99mTc]- 
mAb G250 imaging of tumor-bearing kidneys resulted in 
clear images of RCC, with no mAb G250 uptake being 
observed in normal renal tissue. Despite the low tem pera­
ture (0°-4°C  to assure appropriate pressures) and the rel­
atively short circulation time (16 h), tumor-to-kidney ra ­
tios were approximately 8:1 [25].
Clinical experience
Significant clinical experience with radiolabeled murine 
mAbs that detect TAA has been acquired in the last 
decade [7, 8, 11, 12, 16]. Radioimmunoscintigraphy stud­
ies of RCC with mAbs have been limited, generally being 
restricted to animal models [3,4, 22, 26, 32, 33]. In a clin­
ical study, Vessella et al. [29, 31] examined the imaging/ 
radiotherapeutic ability of mAb A6H in RCC patients. 
Only in 5 of 15 patients examined were positive images 
obtained. This low number of positive images was attrib­
uted to the presence of circulating antigen and the form a­
tion of antigen-antibody complexes. The number of posi­
tive images increased with an altered dosing schedule, but 
the number of imaged lesions remained unsatisfactory. 
The poor performance of A 6H is probably partly attribut­
able to the cross-reactivity with normal tissues, which 
bind antibody, thereby hampering tumor uptake and influ­
encing image quality.
On the basis of our targeting studies in RCC-bearing 
mice and in ex vivo-perfused tumor-bearing kidneys, we 
have performed a phase I protein dose-escalation study 
with 13 ^ -labeled mAb G250 [21]. the primary study ob­
jectives were evaluation of the toxicity, pharmacokinetics, 
and localization capabilities of [131I]-mAb G250, As 
demonstrated by magnetic resonance imaging (MRI) and 
computed tomography (CT) scans more than 90% of pri­
mary and metastatic disease was imaged by [13lI]-mAb 
G250. Metastatic lesions in lymph nodes, bone, and lung 
were visualized. Furthermore, additional metastatic dis­
ease documented at surgery but not detected by MRI and 
CT scans was visualized. For example, radioimmunos­
cintigraphy with [I31I]-mAb G250 showed a small hot 
spot in the liver of one of the patients that was not visual­
ized by other means. The patient showed recurrence o f 
RCC at the [131I]-mAb G250-defined hot spot 9 months 
later. [131I]-mAb G250 imaging also revealed diffuse up­
take in a polycystic kidney of another patient. On the ba­
sis of MRI and CT the process in the polycystic kidney 
was deemed benign. Nevertheless, as based on the [l31I]~ 
mAb G250 findings, surgery was performed at the pa­
tient’s request, and diffuse metastatic RCC was found.
The images obtained by [1311]-mAb G250 were unusu­
ally clear in comparison with other mAb images, with v ir­
tually no background. The only exception was liver up­
take at the lowest dose levels. However, this liver uptake
was c o m p le te ly  saturable, and at the lO-mu dose level and 
hiuher,  no normal on:an uptake was observed. The  small-
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est lesion visualized was 8 nun in d iam eter  (est imate by 
CT).  From the ability of  rnAb G 2 5 0  to yield sharp images 
and visualize small iunior lesions, it was conc luded  that 
m A b  G250 has considerable potential as an imaging agent. 
However,  not all primary or metastatic RCC lesions ex- 
“ess G 250  antigen, or they express it in only a minority 
o f  cells, This  emphasizes  the need for addit ional R C C -
specific m A bs  beeause problems of  antigen heterogeneity  
have to be overcome for therapeutic efficacy.
The  absorbed dose to the tumor  delivered by the best 
inAb/radionuclide combination studies thus far has been
calculated at 2000..3000 cGy, whereby toxic effects of
than grade IV have been maintained [27, 28], Vaughan et 
a.L [27, 2 8 J concluded that the tumor uptake should be in­
creased by a factor of 10 for effective therapy, Calculation 
o f  the maximal fraction of  the injected dose of  [131 I j-mAb 
G 250  recovered in tumor sites showed  that this was eener- 
ally 10-100  times greater than the previously reported ac­
cumulat ion  of radiolabeled rnAb in solid tumors. Similar 
absolute amounts  of [ l3ll | -m A b  G 250  accumulated in 
0 2 5 0 -p o s i t iv e  tumors, irrespective of  the protein dose. 
W hether  Lhis was a reflection o f  tumor saturation is un­
clear. Nevertheless,  the finding that the mean accum ula­
tion o f  the delivered dose, relative as well as absolute, was 
approximate ly  10-fold that of  previously reported rnAb/ra- 
d ionucl ide  combinations indicates that mAb G250 fulfills 
the requirements  of  Vaughan et al.
On the basis of  these findings, a phase I/Ii trail with es ­
calat ing doses of  n i I labeled to 10 mg m A b  G250 was ini-
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bated in patients with inoperable metastatic RCC [5|. Thus 
far, 21 patients have been treated and 90 m C i /m 2 1311 has 
been defined as the maximal tolerable dose. Targeting o f  
radioact ivi ty  to all known sites of  disease was seen in all 
G250-antigen~posit ive patients (19/21). Elevation o f  he­
patic enzym es  was observed in 18 patients, starting at ap ­
prox im ate ly  10 days after treatment and returning to base­
line by 3 weeks posttreatment. This elevation is probably 
attributable to rnAb G250 accumulation in the liver, where 
G 2 5 0  antigen is expressed by large-bile-duct epithelium. 
Exam ina t ion  of liver biopsies obtained in the phase I p ro­
tein dose-escalat ion trial revealed m A b  G 250  accum ula ­
tion in bile-duct epithelium. However,  the amount  of  m A b  
G 2 5 0  necessary to saturate the hepatic com par tm en t  was 
minimal  and  was estimated to be in the range of  200  |Lig. 
Nevertheless ,  this amount seems to be sufficient to induce 
mild liver toxicity on labeling at a higher specific activity. 
Adminis t ra t ion  of  75 m C i/m 2 [ 13lI]-mAb G 250  resulted 
in revers ible  grade IV th rombocytopenia  in 1/6 patients,
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with the nadir  occur r ing  at 4 weeks .  S im i la r  toxicity was 
observed  in 2/3 pat ients  treated with 90  m C i / m 2. No other 
toxicity was seen. N o  response  w as  obse rved ,  but stable 
disease was noted in 11 pat ients  at up to 9 m o n th s  postra­
d io immunotherapy .  In genera l ,  these pa t ien ts  presenting 
with d isseminated  inoperable  p rogress ive  R C C  tend to do 
very  poorly. In the subsequent ,  p h ase  II r a d io im m u n o ­
therapy  study, pa t ien ts  r ece ived  90 m C i / m 2 ( LUI]-mAb 
G25Ö labeled  to 10 m g  prote in .  T h e  side e f fec ts  were 
identical to those seen in the phase  I r ad io im m unotherapy  
trial. M inor  responses  were  seen  in 3 pat ients .  2 of  whom 
had mult ip le  lung métas tasés  (C. R. Divgi,  personal  com ­
municat ion) .
Improved  therapeut ic  eff icacy m ig h t  be ach ievab le  by 
a mul t ip le  dos ing  schedu le .  H o w e v e r ,  adm in is t r a t ion  of 
the m ur ine  m A b s  e l ic i ted  a h u m a n  a n t i -m o u s e  antibody 
( H A M A )  re s p o n s e , p re vent i n g re pe a te cl ad nr i n i s t rat i on . 
For repeated adminis t ra t ion ,  e.g. ,  mul t ip le  r a d io im m u n o ­
therapy or mult iple  t rea tm en t  with naked  an t ibody  to in­
duce an t ibody-dependen t  ce l lu lar  cy to tox ic i ty  (ADCC),  
H A M A  re sp o n ses  n e e d  to be m i n i m i z e d  b e c a u s e  c ircu­
lating H A M A  reduces  the tum o r  up take  o f  m A b  on sub­
sequent  admin is t ra t ion  due  to m A b - H A M A  cross-l inking. 
With recombinant  technology ,  m o u se  m A b  G 2 5 0  variable 
regions were grafted into human I g constant regions. These 
constructs  were t ransfec ted  into m a m m a l i a n  cells,  which
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Fig. 1. A, C Anterior and B, D posterior whole-body images of 
RCC patients receiving A, B 2 or C, D 5 mg 131 (-labeled chimeric 
mAh G250 obtained at 7 days after administration. The relative 
liver uptake decreases with increasing [131 i |-cG250 dose. Tumor 
imaging is evident at both dose levels. Arrowheads point to the tu­
mor masses
Table  I. Comparison of murine and 
chimeric mAh G250 uptake at. the 2-rng 
dose level
% Injected 
dose/ke
Ratio
S
Tissue Chimeric murine
urn
Chimeric murine
Tissue/liver Tissue/kidney
Chimeric murine Chimeric murine
RCC 342-32 1 12-9 924--87 178- 14 65-6 1 8 - 1 1710- 160 285-22
RCC 7 6 -  7 13-3 190--19 1 ¿\— 4 21-2 3-1 19 0 - 19 36- 9
RCC 7 -  5 5-1.5 3-- 2 4 1 6-4 2-1 15- 11 8-  2
Necrosis 0.9-0.55 0.5 1. 1 QA1 0.1 0.2 0.8
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then prodcued chimeric immunoglobulin [17, 18, 34]. 
Substitution of the mouse Fc part by human Fc produces 
the additional advantage that all Fc-related effector func­
tions match the human effector cells. Principally, the use 
of chimeric IgG should augment ADCC-mediated tumor 
cell lysis, and unmodified chimeric mAb might be suit­
able to destroy (minimal) residual disease. Chimerized 
antibodies are expected to be less immunogenic in hu­
mans, allowing multiple treatments.
The chimeric form of mAb G250 (c-G250, IgG I sub­
class) is currently being tested in a phase I protein dose- 
escalation trial to investigate the safety, pharmacokinetics, 
and targeting ability. At the 2-mg dose level, excellent tu­
mor targeting was observed, comparable with that ob­
served at the 2-mg dose level o f the murine form of mAb 
G250 (Fig. 1). Again, normal organ uptake was restricted 
to the liver as expected. The absolute as well as relative 
amounts of C -G 250 delivered to the tumors were similar 
to those observed for murine mAb G250 (Table 1). Con­
sequently, tumor: tissue ratios were also comparable with 
the ratios observed with murine mAb G250 (Table 1), in­
dicating that chimerization of the antibody did not com­
promise the excellent targeting ability of mAb G250. At 
the 5-mg dose level, liver uptake was not visible due to 
the saturation of G250 sites, as was observed for murine 
mAb G250 (Fig. 1). This seems to indicate that the target­
ing ability of the chimeric form of mAb G250 is compa­
rable with that of murine mAb G250 at all dose levels.
Surprisingly, the clearance of C-G250 was comparable 
with that o f murine mAb G250. Apparently, chimerization 
of mAb G250 did not result in the slower clearance ob­
served for other chimerized mAbs [13, 14]. Slower clear­
ance would be disadvantageous for radioimmunotherapy 
because longer retention would result in enhanced bone- 
marrow-related toxicity due to more extensive radiation. 
This would negate the possible benefits of chimerization, 
since the maximum dose of radionuclide would have to be 
reduced. W hether multiple dosing would resolve this dis­
advantage is unclear. Currently we lack information regard- 
ing the immunogenicity of C-G250. However, Buist et al. [2] 
observed m inor human antibody responses to chimerized 
mAb M 0V I8; only 1/25 patients receiving chimeric M0V I8 
developed anti-chimeric M 0V I 8 antibodies. The human 
constant regions of C-M0V I 8 are identical to the human 
constant regions of C-G250, and we therefore expect that 
C-G250 will be immunosilent in the majority of patients.
Our future efforts will be aimed at (multiple dose) ra- 
dioimmunotherapy with chimerized mAb G250. In addi­
tion to 13]I, w e will investigate the possibilities of other 
radionuclides. We are currently investigating the effector 
functions of C-G250. If chimerization results in powerful 
effector functions, “naked” antibody that can coat tumor 
cells and thus activate human effector cells might be an 
attractive alternative to radioimmunotherapy.
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